Subsidiary Aprogen Biologics to issue 50.8B KRW CB
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.15%
Data Coverage
100%n=2535
Risk-adjusted indicator based on 2535 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Total Convertible Bond Amount: 50.8 billion KRW
- • Conversion Price: 3,778 KRW/Share
- • Shares Issuable Upon Conversion: 13,446,267 Shares
- • Dilution Rate (vs. current shares): 93.30%
- • Total Potential Dilution (including existing CBs): 262.78%
- • Purpose of Funds: Debt Repayment (50.8 billion KRW)
AI Analysis Summary
Aprogen Biologics, a subsidiary of Aprogen, Inc., has decided to issue 50.8 billion KRW in private placement convertible bonds (CBs) to repay existing debt. The conversion price is 3,778 KRW per share, potentially issuing 13,446,267 new shares, representing a 93.30% dilution relative to current outstanding shares. Including previously issued CBs, the total potential dilution could reach 262.78%. The CBs carry a 2% surface interest rate and a 4% maturity interest rate, with a maturity date of June 4, 2029. Bondholders have a put option starting December 4, 2027, with varying early redemption rates. This significant dilution, primarily for debt repayment, is a negative for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.